Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

CONCLUSIONS: Data from two placebo controlled, single-attack trials, and an open label study including treatment of multiple attacks, suggested a tendency to relatively better efficacy outcomes when LTN treatment was initiated at mild vs. moderate to severe pain. Further research is needed to better understand the relationship of lasmiditan outcomes to time of administration in the course of a migraine attack.TRIAL REGISTRATION: NCT02439320, NCT02605174, NCT02565186.PMID:33784930 | DOI:10.1080/03007995.2021.1903846

Source: Current Medical Research and Opinion - March 31, 2021 Category: Research Authors: Mario F P Peres Raghavendra Vasudeva Simin K Baygani Ellen B Dennehy Maurice Vincent Deborah I Friedman Source Type: research